Dr. Lal Path Labs Ltd

Transcription

1 Health Care-Health Care Facilities & Svcs Bloomberg Code: DLPL IN India Research - Stock Broking Strong Position in North India, Expanding in South and West Regions: Dr. Lal Path Labs is the second largest diagnostic chain in domestic market with healthy balance sheet and strong cash flows. The company gets 72% of revenue from North India, and is concentrating more on an engagement model between the company and the clients. The future acquisitions and partnerships would provide operating synergies and basis for organic growth in these new regions. Strategic acquisitions and partnerships would provide additional purchasing power with the suppliers and increased economies of scale. The growth drivers for this business are: rising incidence of lifestyle diseases, increase in evidence based treatments, more focus on preventive diseases and wellness, combined with rising incomes and increased penetration of health insurance which can fuel growth of the industry. The company has posted CAGR of 27.2% in gross turnover for FY11-FY16. The company generated 2.% revenue growth for FY16 and we estimate that there would be steady increase in sales of about Rs. 958Mn and Rs.11615Mn in FY17E and FY18E respectively. Increase the breadth of the diagnostic healthcare testing and services platform in the world: The labs in India receive specimens for diagnostic testing from Bhutan, Srilanka, Nepal, Bangladesh, Myanmar, the United Arab Emirates, Oman, Qatar, Kuwait, Kenya, Tanzania and Nigeria. These samples are imported in compliance with the Indian Council of Medical Research (ICMR). Paliwal Diagnostics and Paliwal Medicare networks in Kanpur act as mini hub. The company offers tests and services which cover a range of specialities and disciplines for use in core testing like Routine testing, Specialized testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Valuation and Outlook At CMP of Rs.983, Dr. Lal Path Labs is currently trading at P/E of 5.3x on FY18E EPS of Rs Based on DLPL s growth prospects and estimated increase in the operations nationwide, we value the company at 1SD P/E of 6.6x of FY18E EPS for the target of Rs We initiate coverage on DLPL with a BUY rating for a target price of Rs.1182 representing an upside potential of 2% in 9-12 month period. Key Risks yintense competition. yretention of critical staff. Recommendation (Rs.) Jul 18, 216 BUY CMP (as on Jul 15, 216) 983 Target Price 1182 Upside (%) 2 Stock Information Mkt Cap (Rs.mn/US$ mn) / wk High/Low (Rs.) 146 / 696 3M Avg. daily volume 6252 Beta (x) NA Sensex/Nifty / 8541 O/S Shares(mn) 82.7 Face Value (Rs.) 1. Shareholding Pattern (%) Promoters 58.7 FIIs 29.3 DIIs 6.2 Others 5.9 Stock Performance (%) 1M 3M 6M Absolute 3 (3) 25 Relative to Sensex (1) (11) 9 Source: Bloomberg Relative Performance* Dec-15 Jan-16 Jan-16 Feb-16 Feb-16 Source: Bloomberg; *Index 1 Apr-16 Apr-16 May-16 May-16 Sensex Jul-16 Exhibit 1: Valuation Summary YE Mar (Rs. Mn) FY14 FY15 FY16 FY17E FY18E Net Sales EBITDA EBITDA Margin (%) Adj. Net Profit EPS (Rs.) RoE (%) PE (x) For private circulation only. For important information about Karvy s rating system and other disclosures refer to the end of this material. Karvy Stock Broking Research is also available on Bloomberg, KRVY<GO>, Thomson Publishers & Reuters Analyst Contact Shamshad Sajitha Gunturi shamshad.sajitha@karvy.com 1

2 Company Financial Snapshot (Y/E Mar) Profit & Loss (Rs. Mn) FY16 FY17E FY18E Net sales Optg. Exp (Adj for OI) EBITDA Depreciation Interest Other Income PBT Tax Adj. PAT Profit & Loss Ratios EBITDA margin (%) Net margin (%) P/E (x) EV/EBITDA (x) Dividend yield (%) Balance sheet (Rs. Mn) FY16 FY17E FY18E Total Assets Net Fixed assets Current assets Other assets Total Liabilities Networth Debt Current Liabilities Other liabilities Balance Sheet Ratios RoE (%) RoCE (%) Net Debt/Equity (.5) (.5) (.6) Equity/Total Assets P/BV (x) Exhibit 2: Shareholding Pattern (%) Company Background Dr. Lal Path Labs has been founded by Dr.Major S.K.Lal in Later, in 1995, it was incorporated as Dr.Lal Path Labs Pvt.ltd. It has a pan India integrated coverage with 172 clinical labs, built a national hub-and-spoke network that includes its National Reference Lab at Delhi, 1559 patient service centers and nearly 5 pick-up points. Their customers include individual patients, hospitals, other healthcare providers and corporate customers. It is well positioned and fastest growing segment in the Indian healthcare industry. Three clinical labs received NABL (National Accreditation Board for Calibration and Testing Laboratories) accreditation in 2. Received ISO 91:28 certification in 21 and received International Accreditation from CAP (College of American Pathologists). Having strong presence in North India domestic market, the company gets 72% of business from north India. The company has 4 employees including full time consultants, pathologists, phlebotomists and radiologists. Cash Flow (Rs. Mn) Exhibit 3: Revenue Segmentation (%) FY16 FY17E FY18E PBT Depreciation Interest (net) Tax (687) (716) (889) Changes in WC CF from Operations Capex (441) (558) (61) Investment (922) Others (155) CF from Investing (1518) (558) (61) Dividends (156) (189) (189) Others 16 (8) (1) CF from Financing 4 (198) (199) Change in Cash (46) FIIs 29.3% DIIs 6.2% Others 5.9% Walk-in Patients 67.% Promoters 58.7% Institutions (Super specialised) 33.% Source: BSE, Karvy Research 2

3 Industry Outlook Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance and medical equipment. The Indian healthcare sector is growing at a fast pace due to its strengthening coverage, services and increasing expenditure by public as well as private players. The Department of Health Research (DHR) planned to establish a 3-tier Viral Research & Diagnostic Laboratories (VRDLs) throughout the country. This Scheme was approved by the Cabinet Committee on June 27, 213 for implementation during the 12th Plan Period ( to ). The aforesaid scheme entails establishment of 1 Regional Level Labs, 3 State Level Labs and 12 Medical College Level Labs in the State Government Medical Colleges for timely diagnosis and management of viral epidemics and new viral infection at an estimated cost of Rs Mn (Central Share Rs Mn + State Share Rs Mn). The geographic spread of the laboratories is ensured by establishing the labs across the country. The Government initiative would be of Public Private Partnership (PPP) model. India has a competitive edge over its peers of Asia and western countries with large pool of well trained medical professionals; and also in terms of cost of surgery in India which is about one-tenth of that in the USA or western Europe. The overall Indian healthcare market today is worth about US$1 Bn and is expected to grow to US$28 Bn by 22, at a CAGR of 22.9%. The global healthcare expenditure is increasing due to rising incomes, easier access to high-quality healthcare facilities and greater awareness of personal health and hygiene. Greater penetration of health insurance aided the rise in healthcare spending, a trend likely to intensify in the coming decade. Economic prosperity is driving the improvement in affordability for generic drugs in the market. Exhibit 4: Indian Healthcare sector growth trend (US$ Bn) E 22E Healthcare sector growth trend (US$ Bn) Source:Health Resource Guide India, Karvy Research Exhibit 5: Global Healthcare Expenditure Forecast, E 217E 218E Global Healthcare Expenditure Forecast, (US$ Tn) Source: World Health Organization (WHO) data, Karvy Research Healthcare delivery, which includes hospitals, nursing homes, diagnostic centers and pharmaceuticals, constitutes 65% of the overall market. There is a significant scope for enhancing healthcare services considering that healthcare spending as a percent of Gross Domestic Product (GDP) is rising. The rural India which constitutes of 7% of the Indian population is set to emerge as potential demand source. India requires 6 to 7 additional beds over the next five to six years, indicative of an investment opportunity of US$25-3 Bn. The Indian medical tourism industry is pegged at US$3 Bn per annum, with tourist arrivals estimated at 23. The Indian medical tourism industry is expected to reach US$6 Bn by 218, with the number of people arriving in the country for medical treatment set to double over the next four years. With greater number of hospitals and diagnostic labs getting accredited, receiving recognition and greater awareness on the need to develop their quality to meet international standards. The hospital and diagnostic centers attracted Foreign Direct Investment (FDI) worth US$3.4 Bn between April 2 and December 215, according to data released by the Department of Industrial Policy and Promotion (DIPP). India is a land full of opportunities for players in the medical devices industry. The country has also become one of the leading destinations for high-end diagnostic services with tremendous capital investment for advanced diagnostic facilities, thus catering to a greater proportion of population. With increased private participation, the healthcare sector has also witnessed rise in FDI inflows. The Government of India (GoI) has permitted 1% FDI for all health-related services under automatic route. 3

4 Indian per capita health spending stands at just $132 (on a PPP-adjusted basis), ranking 145th amongst WHO nations and less than 2% of the $8,632 spent in the United States. India s annual healthcare expenditure stands at just $77 Bn, against $3 Bn in China, despite the fact that India is expected to surpass China as the most populous nation in the next 2 years. Exhibit 6: Indian per capita spending in healthcare ($ Bn) Exhibit 7: Annual Healthcare Expenditure ($ Bn) India $132 India $77 China $3 USA $8632 Source: Healthcare Resource Guide:India, Karvy Research Source: Healthcare Resource Guide:India, Karvy Research Exhibit 8: Highly Fragmented Industry Hospital Based 37.% Diagnostic chain 15.% Standalone centres 48.% Dr Lal Path labs, which is the second largest diagnostic chain in India, has become one of the fastest growing. Diagnostics industry is about 9% of the total healthcare market. The Indian diagnostics industry is about Rs.37 Bn, where unorganized sector consists of 85%; and 48% is of standalone private labs, 37% of hospitals managed labs and the remaining 15% by Diagnostic chains. Of the 15% share of Diagnostic chains, only about 6% share is with the diagnostic chains with pan India presence. Exhibit 9: No. of Clinical Labs of the company No.of Clinical Laboratories The company s core markets are northern, eastern and central India and this market is highly fragmented. There are lot of small independent labs, and the company is attempting to make acquisitions from unorganized players. The way they are providing services is creating a consumer facing healthcare brand and also scaling it up by opening lot of franchise collection centers with large pan India network. The company is operating with 172 labs which increased from 131 labs in FY13. The patient service centers increased from 824 centers in 213 to 1559 in 216. DLPL is also penetrating through the pick-up points, where they serve collecting samples from hospitals as well as from small independent labs. Exhibit 1: No. of Patient Service Centers Exhibit 11: No. of Pick-up Points (PUPs) No.of Patient Service Centers No.of Pick-up Points (PUPs) 4

5 The services offered are: y Routine clinical laboratory tests-such as blood chemistry analyses and blood cell counts; Jul 18, 216 y Specialized testing services-such as histopathology analyses, genetic marker-based tests, viral and bacterial cultures and infectious disease tests; and ypreventive testing services-such as screenings for hypertension, heart disease and diabetes. These tests and services in the clinical laboratories are done using sophisticated and computerized instruments. Exhibit 12: India, Highly under-penetrated market 2% 16% 12% 8% 4% 3.1% 4.% 4.% % 4.6% 5.6% 6.% 6.6% 9.1% 9.7% 17.1% India has 85% of unorganized diagnostic segment; and 48% is of independent small labs, 37% being maintained by the hospitals reaching their services to limited patients. There is a huge market to explore in this segment, DLPL is attempting to capture the domestic market with huge network building, acquisitions of independent labs and increasing number of franchisees. It is penetrating with Hub-and-Spoke model through centralized IT platform. The company is promoting its brand awareness, working in the rural areas and testing seasonal diseases at competitive cost for the general public. With strategic acquisitions and partnerships, it is spreading its wings all over the country deepening in the existing markets. What is driving the company with increase in volumes was building trust among the customers, both corporate doctors and individual patients, based on quality and accurate reports, the strong process in the organization and the accreditations making accessible by going closer to the patients. Timely delivery of reports and convenience to the walk-in patients keep them have an edge over the competitors. With increased health consciousness, communicable diseases and weather conditions giving scope for the industry to churn revenues throughout the year. The seasonal business starts from July-September even extend to October, with diseases like dengue, malaria or chicken gunea outbreak. Again from January to March, the cycle resumes. Exhibit 13: Revenue by Geography Exhibit 14: Hub-and-Spoke Model West India 7.% PSC* PSC North India 72.% South India 7.% East India 13.% International 1.% Clinical Lab Reference Lab Clinical Lab PSC PSC PSC PSC, *PSC: Patient Service Center 5

6 Exhibit 15: Business Assumptions Y/E Mar (Rs. Mn) FY15 FY16 FY17E FY18E Comments Revenue Revenue Growth (%) EBITDA EBITDA Margins (%) PAT (normalized) Net CFO Debt Capex (353) (441) (558) (61) Free Cash Flow Revenues grown to Rs.7913 Mn in FY16 from Rs Mn in FY15, representing a YoY of 2.%. The contribution to revenues for FY16 from the North Indian market stood at 72%. The East zone contributed 13%. We estimate that there would be steady increase in sales of about Rs. 958 Mn and Rs.11615Mn in FY17E and FY18E respectively. EBITDA during FY16 showed 34.5% YoY growth to Rs. 297 Mn following healthy accretion to top line and impact from dearness in reagents and consumables. EBITDA reflects the effect of high volumes from dengue testing undertaken in FY16. For FY17E and FY18E, it is expected that there would be 1.5% and 1.7% dip in EBITDA margins respectively, as other expenses are increasing with expansion and building-up capabilities for larger scale of economic benefits. 6

7 Exhibit 16: Revenue (Rs. Mn) & Revenue Growth (%) % 4517 FY % 2.2% 23.5% 2.% 18.2% FY14 FY FY FY17E FY18E 4% 3% 2% 1% % Revenue (Rs. Mn) Revenue Growth (%) Jul 18, 216 On YoY, FY16 has seen a 2.% growth with revenues increasing to Rs.7913 Mn, with the outbreak of seasonal borne diseases like dengue, in Q3FY16. Dr. Lal Path Labs has acquired the small scale labs near Kanpur. With Hub-and-Spoke model, where one central reference lab would act as a hub and the clinical labs and the patient service centers are well integrated to reach out to the patients. With new Regional Reference labs coming up in Lucknow and Kolkata, within a span of 18 months, the diagnostic labs are expected to reach to more patients generating more volumes in sales. Coverage in metros, Tier1 and Tier2 cities, 24*7 access including online collection and home collection with dedicated logistics team stand as strong pillars for the company. We estimate that with all these strengths, the company is expected to grow its revenues to Rs. 958 Mn for FY17E and Rs Mn for FY18E. Exhibit 17: EBITDA (Rs. Mn) & EBITDA Margins (%) % 977 FY % 26.5% 25.% 24.8% 23.6% 1386 FY FY FY FY17E 288 FY18E 28% 26% 24% 22% 2% EBITDA (Rs. Mn) EBITDA Margins (%) EBITDA Margin is expected to come down approximately by 1.5% in FY17E and 1.7% in FY18E respectively, compared to EBITDA margins of FY16. The cost of reagents, chemicals, surgicals and laboratory supplies consumed used in the diagnostic healthcare services and tests are the largest expense to the company earlier; but from FY11-FY15, it has been decreased primarily with greater economies of scale, the number of diagnostic healthcare tests and services performed grew, it enabled the process of healthcare tests and services more efficiently at lower costs and the bargaining power with the suppliers. The other expenses are growing YoY indicating they are spending much of their accruals on fees to franchisee patient service centers, rental expenses, sales promotion expenses, periodic remodeling and refurbishing at patient service centers. These expenses are expected to increase in near to mid-term at a rate higher than earlier due to contemplated expansion where higher associated costs are involved. Exhibit 18: EBIT (Rs. Mn) & EBIT Margins (%) % 21.3% 22.9% 21.% 2.% 19.4% FY13 FY14 FY15 FY16 FY17E FY18E 25% 23% 21% 19% 17% 15% EBIT (Rs. Mn) EBIT Margins (%) EBIT margins have been increased by 35 basis points at 22.9% for FY16. The company on an average is setting up 15-2 satellite labs yearly, with each lab costing almost Rs. 7.5 Bn to Rs. 1 Bn. In coming years with long term expansions in line, the increased capex maintenance is estimated to bring down the EBIT, as EBIT margin is expected to dip by 1.9% and 1.6% for FY17E and FY18E respectively. Exhibit 19: EPS (Rs.) Earnings per share of DLPL is estimated to be at Rs.15.7 and Rs for FY17E and FY18E respectively. 9 FY13 FY14 FY15 FY16 FY17E FY18E EPS (Rs.) 7

8 Exhibit 2: RoE & RoCE (%) 4% 35% 3% 25% 2% 15% 34.% 34.4% 3.6% 31.3% 28.% 26.1% 26.3% 24.7% 21.1% 21.2% 2.1% 2.3% FY13 FY14 FY15 FY16 FY17E FY18E RoE (%) RoCE (%) DLPL has maintained consistently healthy return ratios. The company s RoE and RoCE are in the range of 26.1% and 24.7% respectively for FY16. We anticipate the company to outperform in the industry with its RoE for FY17E and FY18E at 21.1% and 21.2% respectively; and RoCE in the range of 2.1% and 2.3% in FY17E and FY18E respectively, though there may be a slight dip in percentage terms for FY17E, FY18E vis-a-vis FY16. Its net debt to equity is -.5x and -.6x for FY17E and FY18E respectively, on a consolidated basis. Exhibit 21: Company Snapshot (Ratings) Low High Quality of Earnings 33 Domestic Sales 33 Exports 33 Net Debt/Equity 33 Working Capital Requirement 33 Quality of Management 33 Depth of Management 33 Promoter 33 Corporate Governance 33 8

9 Valuation & Outlook At CMP of Rs.983, Dr. Lal Path Labs is currently trading at P/E of 5.3x on FY18E EPS of Rs Based on DLPL s growth prospects and estimated increase in the operations nationwide, we value the company at 1SD P/E of 6.6x of FY18E EPS for the target of Rs We initiate coverage on DLPL with a BUY rating for a target price of Rs.1182 representing an upside potential of 2% in 9-12 month period. Exhibit 22: PE Band Dec-15 Dec-15 Jan-16 Jan-16 Jan-16 Jan-16 Feb-16 Feb-16 Feb-16 Feb-16 Apr-16 Apr-16 Apr-16 Apr-16 May-16 May-16 May-16 May-16 Jul-16 Jul-16 Source: Bloomberg, Karvy Research Average P/E P/E 1SD 2SD -1SD Key Risks yintense competition. yretention of critical staff. ygeographical concentration of small labs. 9

10 Financials Exhibit 23: Income Statement YE Mar (Rs. Mn) FY14 FY15 FY16 FY17E FY18E Revenues Growth (%) Operating Expenses EBITDA Growth (%) Depreciation & Amortization Other Income EBIT Interest Expenses PBT Tax Adjusted PAT Growth (%) (1.6) 24.1 Exhibit 24 Balance Sheet YE Mar (Rs. Mn) FY14 FY15 FY16 FY17E FY18E Cash & Cash Equivalents Sundry Debtors Inventory Loans & Advances Investments Other current Assets Net Block CWIP Total Assets Current Liabilities & Provisions Debt Other Liabilities Total Liabilities Shareholders Equity Reserves & Surplus Total Networth Total Networth & Liabilities

11 Exhibit 25: Cash Flow Statement YE Mar (Rs. Mn) FY14 FY15 FY16 FY17E FY18E PBT Depreciation Interest Tax Paid (53) (534) (687) (716) (889) Inc/dec in Net WC Other non cash items (139) (31) 36 Cash flow from operating activities Inc/dec in capital expenditure (328) (353) (441) (558) (61) Inc/dec in investments (734) (845) (922) Others (155) Cash flow from investing activities (897) (1135) (1518) (558) (61) Dividend paid (97) (14) (156) (189) (189) Interest paid (5) (1) (8) (8) (1) Others Cash flow from financing activities (12) (8) 4 (198) (199) Net change in cash (19) 75 (46) Exhibit 26: Key Ratios YE Mar FY14 FY15 FY16 FY17E FY18E EBITDA Margin (%) EBIT Margin (%) Net Profit Margin (%) Dividend Payout Ratio (%) Net Debt/Equity (x) (.5) (.4) (.5) (.5) (.6) RoE (%) RoCE (%) Exhibit 27: Valuation Parameters YE Mar FY14 FY15 FY16 FY17E FY18E EPS (Rs.) DPS (Rs.) BV (Rs.) PE (x) P/BV (x) EV/EBITDA (x) EV/Sales (x)

12 Stock Ratings Absolute Returns Buy : > 15% Hold : 5-15% Sell : <5% Connect & Discuss More at (Toll Free) research@karvy.com Live Chat f in You Tube Disclaimer Analyst certification: The following analyst(s), Shamshad Sajitha Gunturi, who is (are) primarily responsible for this report and whose name(s) is/are mentioned therein, certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report. Disclaimer: Karvy Stock Broking Limited [KSBL] is a SEBI registered Stock Broker, Depository Participant, Portfolio Manager and also distributes financial products. KSBL has filed an application with SEBI, seeking registration as a Research Analyst and such application is pending for disposal. The subsidiaries and group companies including associates of KSBL provide services as Registrars and Share Transfer Agents, Commodity Broker, Currency and forex broker, merchant banker and underwriter, Investment Advisory services, insurance repository services, financial consultancy and advisory services, realty services, data management, data analytics, market research, solar power, film distribution and production, profiling and related services. Therefore associates of KSBL are likely to have business relations with most of the companies whose securities are traded on the exchange platform. The information and views presented in this report are prepared by Karvy Stock Broking Limited and are subject to change without any notice. This report is based on information obtained from public sources, the respective corporate under coverage and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KSBL. While we would endeavor to update the information herein on a reasonable basis, KSBL is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent KSBL from doing so. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KSBL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. This material is for personal information and we are not responsible for any loss incurred based upon it. The investments discussed or recommended in this report may not be suitable for all investors. Investors must make their own investment decisions based on their specific investment objectives and financial position and using such independent advice, as they believe necessary. While acting upon any information or analysis mentioned in this report, investors may please note that neither KSBL nor any associate companies of KSBL accepts any liability arising from the use of information and views mentioned in this report. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Past performance is not necessarily a guide to future performance. Forward-looking statements are not predictions and may be subject to change without notice. Actual results may differ materially from those set forth in projections. y Associates of KSBL might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. y Associates of KSBL might have received compensation from the subject company mentioned in the report during the period preceding twelve months from the date of this report for investment banking or merchant banking or brokerage services from the subject company in the past twelve months or for services rendered as Registrar and Share Transfer Agent, Commodity Broker, Currency and forex broker, merchant banker and underwriter, Investment Advisory services, insurance repository services, consultancy and advisory services, realty services, data processing, profiling and related services or in any other capacity. y KSBL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. y Compensation of KSBL s Research Analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions. y KSBL generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. y KSBL or its associates collectively or Research Analysts do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report. y KSBL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report and have no financial interest in the subject company mentioned in this report. y Accordingly, neither KSBL nor Research Analysts have any material conflict of interest at the time of publication of this report. y It is confirmed that KSBL and Research Analysts, primarily responsible for this report and whose name(s) is/ are mentioned therein of this report have not received any compensation from the subject company mentioned in the report in the preceding twelve months. y It is confirmed that Shamshad Sajitha Gunturi, Research Analyst did not serve as an officer, director or employee of the companies mentioned in the report. y KSBL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. y Neither the Research Analysts nor KSBL have been engaged in market making activity for the companies mentioned in the report. y We submit that no material disciplinary action has been taken on KSBL by any Regulatory Authority impacting Equity Research Analyst activities. Karvy Stock Broking Limited Plot No.31, 6th Floor, Karvy Millennium Towers, Financial District, Nanakramguda, Hyderabad, 5 32, India Tel: ; Fax: For More updates & Stock Research, visit 12